ReviewJournal of pharmaceutical analysis2026
Promising TNF-α inhibitors: Targeting pathogenic TNF-α/TNFR signaling to restore Th17/Treg balance in rheumatoid arthritis.
Review in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Gut-Bone Axis and Skeletal Health: Regulatory Mechanisms and Therapeutic Applications of Plant-Derived Bioactive Compounds.Biomolecules · 2026Pooled it
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Association of serum TNF-α, IL-17 A, and IL-17 F levels with disease activity in Yemeni patients with rheumatoid arthritis.Scientific reports · 2026Article
- Role of T cells and cytokines in the pathogenesis of rheumatoid arthritis.Biochemistry and biophysics reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pleiotropic regulatory effect of tumor necrosis factor-alpha (TNF-α), an essential cytokine involved in immune regulation, is of significant importance in the immune response. TNF-α inhibitors have been widely used in rheumatoid arthritis (RA) and other autoimmune diseases since their introduction into clinical practice. However, the tradeoff between its excellent efficacy and adverse drug reactions (ADR) remains a problem. T cells, especially the T helper cell 17 (Th17)/regulatory T (Treg) cells balance, are crucial for the treatment of autoimmune diseases including RA. This review explores the mechanisms by which TNF-α/TNF receptor (TNFR) signaling induces Th17/Treg imbalance in RA. This review synthesizes current knowledge to facilitate an improved understanding of the causes of ADR, such as infection caused by TNF-α inhibitors in clinical practice. Moreover, our findings offer a reference for exploring potential TNF-α/TNFR signaling inhibitory strategies from the perspective of regulating T cell balance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.